Specifically, multivariate analysis pinpointed SLC3A2 (HR = 1.630, 95% CI [1.066–2.492], P = 0.024), IDH status (HR = 0.481, 95% CI [0.293–0.792], P = 0.004), 1p/19q codeletion (HR = 0.448, 95% CI [0.258–0.778], P = 0.004), Primary therapy outcome, and Age (HR = 1.058, 95% CI [1.041–1.074], P < 0.001) as independent prognostic arbiters for glioma OS. This evidence concerns the gene SLC3A2 and glioma.